Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey

Current treatment modalities can cure up to 70–80 % of patients with classical Hodgkin lymphoma. Approximately, 20–30 % of patients require further treatment options. Brentuximab vedotin has been approved for the treatment of relapsed and refractory Hodgkin lymphoma. In the present study, we report...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Ann Hematol
Päätekijät: Salihoglu, A., Elverdi, T., Karadogan, I., Paydas, S., Ozdemir, E., Erdem, G., Karadurmus, N., Akyol, G., Kaynar, L., Yegin, ZA, Sucak, G., Ozkocaman, V., Topcuoglu, P., Ozcan, M., Birtas, E., Goker, H., Baslar, Z., Ferhanoglu, B.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Springer Berlin Heidelberg 2014
Aiheet:
Original Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4317523/
https://ncbi.nlm.nih.gov/pubmed/25231929
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00277-014-2215-9
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia